TL;DR
This meta-analysis of 14 randomized controlled trials (RCTs) involving 1,109 gastric cancer patients found that combining Traditional Chinese Medicines (TCMs) with paclitaxel-based chemotherapy significantly improves tumor response rates and patient quality of life, while also reducing common chemotherapy side effects. The findings suggest TCMs could be a valuable adjunct therapy for gastric cancer, though larger, high-quality RCTs are needed for confirmation.
What Problem Does This Paper Address?
Gastric cancer (GC) remains a significant global health challenge, being the fifth most commonly diagnosed cancer and a leading cause of cancer-related death. While chemotherapy, particularly paclitaxel-based regimens, is a cornerstone of treatment, its efficacy is often limited by drug resistance and significant side effects. This creates a need for complementary or alternative approaches that can enhance treatment outcomes and improve patient well-being. Traditional Chinese Medicines (TCMs) have a long history of use in China for various ailments, including cancer, and are often employed to mitigate chemotherapy side effects and boost efficacy. However, robust evidence comparing paclitaxel-based chemotherapy with and without TCMs for gastric cancer has been fragmented, necessitating a comprehensive analysis to clarify their combined impact.
Methods
The researchers conducted a systematic meta-analysis, a statistical technique that combines the results of multiple independent studies to derive a pooled estimate of the treatment effect. They performed extensive literature searches across major databases (PubMed, EMBASE, Cochrane Library, and Chinese databases like CNKI and Wanfang) to identify relevant randomized controlled trials (RCTs) published up to September 25, 2019. The inclusion criteria focused on RCTs comparing paclitaxel-based chemotherapy combined with TCMs against paclitaxel-based chemotherapy alone for gastric cancer. Key outcomes assessed included tumor response rate (TRR), quality of life (measured by the Karnofsky Performance Scale - KPS), and various chemotherapy-related side effects (neutropenia, leukopenia, thrombocytopenia, anemia, nausea/vomiting, hepatic dysfunction, and neurotoxicity). The quality of included studies was assessed using the Jadad scale, and risk of bias was evaluated using the Cochrane Collaboration's tool. Statistical analysis involved calculating risk ratios (RR) with 95% confidence intervals (CI) and assessing heterogeneity using Cochran's Q test and the I² statistic.
Datasets
Not applicable. This paper is a meta-analysis of existing studies and does not introduce new datasets or benchmarks.
Key Insights and Ideas
- Synergistic Efficacy: The most striking insight is that TCMs don't just mitigate side effects; they actively enhance the efficacy of paclitaxel chemotherapy, leading to better tumor response. This suggests a potential synergistic interaction rather than a purely supportive role.
- Quality of Life Matters: Beyond tumor shrinkage, the combination therapy significantly improved patients' quality of life, as measured by the KPS score. This highlights the importance of considering patient-reported outcomes in cancer treatment.
- Targeted Side Effect Reduction: The meta-analysis identified specific side effects that are significantly reduced by TCM co-administration, particularly blood-related toxicities (neutropenia, leukopenia, thrombocytopenia) and gastrointestinal distress (nausea and vomiting). This offers a more nuanced understanding of TCM's benefits.
- Common TCM Combinations: The study identified frequently used TCM ingredients and combinations, such as Dangshen and Gancao, and the "Sijunzi Decoction" (Dangshen, Gancao, Baizhu, and Fuling). This provides valuable insights for clinicians and researchers looking to standardize TCM regimens.
Key Results
The meta-analysis included 14 RCTs with 1,109 participants. Key findings include:
- Tumor Response Rate (TRR): Significantly improved with paclitaxel + TCM compared to paclitaxel alone (RR: 1.39; 95% CI: 1.24–1.57; p < 0.001). This improvement was consistent across oral and injection TCM administration routes and different TNM stages.
- Quality of Life (KPS): Significantly increased with paclitaxel + TCM (RR: 1.53; 95% CI: 1.19–1.96; p < 0.001).
- Side Effects:
- Reduced: Neutropenia (RR: 0.68; 95% CI: 0.55–0.84; p < 0.001), leukopenia (RR: 0.69; 95% CI: 0.54–0.90; p < 0.01), thrombocytopenia (RR: 0.66; 95% CI: 0.46–0.96; p < 0.05), and nausea/vomiting (RR: 0.50; 95% CI: 0.32–0.80; p < 0.01).
- Similar: Hepatic dysfunction (RR: 0.63; 95% CI: 0.33–1.20; p = 0.16), neurotoxicity (RR: 0.64; 95% CI: 0.26–1.55; p = 0.32), and anemia (RR: 0.65; 95% CI: 0.40–1.04; p = 0.07).
- Publication Bias: A funnel plot indicated potential publication bias for TRR data.
Limitations and Future Work
The authors acknowledge several limitations:
- Study Quality: The included studies were often small and lacked large, multicenter, standardized designs, which could introduce bias.
- Lack of Data: Some studies had missing data, and a comprehensive assessment of all potential side effects was not always possible.
- Paclitaxel Resistance: The current analysis did not specifically assess the efficacy of TCMs in paclitaxel-resistant patients, which is a crucial area for future research.
The authors strongly recommend that future research focus on conducting large, high-quality RCTs to confirm these findings and further investigate the role of TCMs in combination therapies, particularly in addressing drug resistance and optimizing treatment regimens.
Summary updated